I want another expert opinion.
Understand your diagnosis, compare recommendations and prepare for an informed decision.
Explore a second opinion
Chirona is a global cancer treatment navigation platform connecting patients with world-class medical experts and advanced therapies.
Facing a new diagnosis or looking for your next treatment option? Start with your situation. We’ll help you understand what to explore next.
You don’t need to know a treatment name to begin.
Understand your diagnosis, compare recommendations and prepare for an informed decision.
Explore a second opinionExplore further medicines, specialist approaches and relevant clinical trials.
Explore further optionsArrange specialist review of surgery and other treatments that may fit your situation.
Explore surgical assessmentCompare treatment access, costs and the practical steps involved in care abroad.
Explore care abroadSix medicines with approved uses in China. Start with the cancer type and treatment situation that relates to you.
Ivonescimab
An immunotherapy that also targets signals involved in tumor blood-vessel growth. Chinese approvals include specific first-line advanced non-small cell lung cancer settings and treatment after EGFR-targeted therapy.
Your cancer subtype, biomarker results and previous treatment determine the relevant regimen.
Explore this treatmentSKB264 · sac-TMT
An antibody that carries a cancer-killing medicine to tumor cells. Chinese approvals cover previously treated triple-negative or HR-positive/HER2-negative breast cancer, and EGFR-mutated nonsquamous lung cancer after targeted therapy.
Required previous treatments differ by cancer type.
Explore this treatmentCT041 · satri-cel
A cell therapy that modifies your own immune cells to recognize a marker on cancer cells. Approved in China for advanced gastric or gastroesophageal junction adenocarcinoma.
For CLDN18.2-positive, HER2-negative disease after at least two previous lines of treatment have failed.
Explore this treatmentiza-bren
A dual-target antibody–drug conjugate approved in China for recurrent or metastatic nasopharyngeal cancer after at least two chemotherapy lines and PD-1/PD-L1 treatment have failed.
Also approved for adults with recurrent or metastatic esophageal squamous cell cancer after PD-1/PD-L1 treatment combined with platinum chemotherapy has failed.
Explore this treatmentMRG003
An EGFR-targeted antibody–drug conjugate. Conditionally approved in China for adults with recurrent or metastatic nasopharyngeal cancer.
After at least two chemotherapy lines and PD-1/PD-L1 treatment have failed. Previous medicines and side effects help guide specialist assessment.
Explore this treatmentCadonilimab
A medicine targeting two immune checkpoints. Chinese approvals include first-line combinations for specified advanced cervical and gastric cancers, and treatment after platinum chemotherapy for recurrent or metastatic cervical cancer.
These approved uses do not require PD-L1 positivity. Previous treatment and overall health still matter.
Explore this treatmentTreatment suitability, risks and availability require review by the treating team.
Start with your diagnosis and treatment history. We help organize the information needed for specialist review.

Your next step may involve surgery, radiotherapy, medicines or a combination. We help bring the relevant expertise together around your case.
Seek an experienced opinion on whether an operation is appropriate, what it could achieve and how it fits with other treatment.
Understand when advanced radiotherapy, including proton therapy, may be worth discussing for your cancer and treatment goals.
Explore whether treatment directed at a particular tumor or area of disease belongs in your overall care plan.
A hospital’s reputation is a starting point. The right specialty, experience with your cancer and ability to deliver the proposed treatment make the choice relevant to you.
We help identify appropriate teams, prepare your records and coordinate specialist opinions and hospital arrangements.

Looking beyond your home country can open up different treatment and cost options. Compare medical costs, travel needs and coordination services before deciding.
| Published reference | Treatment-cost reference |
|---|---|
| China · government-guided course pricing (2026) | Around US$25,000CNY 170,000 per course |
| US · Oklahoma Proton Center (published 2022) | US$25,000–100,000+Published course range |
Published references, not individual quotes or guaranteed savings. Treatment scope, insurance and hospital charges differ. Travel, accommodation and coordination are additional. Approximate conversion: CNY 6.70 per US dollar.
Share your current diagnosis or the treatment you are considering. We help clarify what is needed for a hospital estimate and the other costs to plan for.
Tell us your diagnosis, previous treatment and main questions. Begin with the medical records you already have.
Initial feedback and a list of any additional information needed.
We coordinate review with an appropriate team and help you understand the feedback and possible care directions.
Specialist feedback and guidance on what to consider next.
If you decide to proceed and the hospital accepts your case, we help coordinate appointments, travel, interpretation and follow-up communication.
Confirmed arrangements and a clear point of contact.
Tell us what you know, what you have already tried and what you are hoping to understand. We’ll help you organize the next step.
Start a confidential case reviewPrefer email? support@chironahealth.com
No. Start with your diagnosis, treatment history and the questions you want a specialist to address.
Yes. Tell us your relationship to the patient and make sure you have permission to share their information.
You can begin by sharing existing records. We help coordinate preliminary review before travel; the receiving team will explain whether an in-person assessment is needed.